Results 1 to 10 of about 162,220 (306)

Comorbidities in interstitial lung diseases [PDF]

European Respiratory Review, 2017
Fibrosing lung disorders include a large number of diseases with diverse behaviour. Patients can die because of the progression of their illness, remain stable or even improve after appropriate treatment has been instituted.
George A. Margaritopoulos, Katerina M. Antoniou, Athol U. Wells   +2 more
doaj   +4 more sources

Comparative survival analysis between idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis

Pulmonology, 2020
Introduction Chronic hypersensitivity pneumonitis (CHP) is an interstitial lung disease with limited treatment response and bad prognosis. Sometimes it is indistinguishable from idiopathic pulmonary fibrosis (IPF) becoming one of the main differential ...
Maria Laura Alberti, Jose María Malet Ruiz, Martin Eduardo Fernández, Leandro Fassola, Fabián Caro, Ivette Buendía Roldán, Francisco Paulin   +6 more
doaj   +3 more sources

Long-term nitrofurantoin: an analysis of complication awareness, monitoring, and pulmonary injury cases

BJGP Open, 2021
Background: Long-term nitrofurantoin (NF) treatment can result in pulmonary and hepatic injury. Current guidelines do not outline the type or frequency of monitoring required for detection of these injuries.
Toby Peter Speirs, Nicole Tuffin, Finlay Mundy-Baird, Helena Sakota, Sarah Mulholland, Michelle Westlake, Max Lyon, Andrew R Medford, Charles Sharp, Michael Darby, Mahableshwar Albur, Francis Keeley, Helena Burden, Charlie Kenward, Elizabeth Jonas, Shaney Barratt, Huzaifa I Adamali   +16 more
doaj   +1 more source

Differentiating interstitial lung diseases from other respiratory diseases using electronic nose technology

Respiratory Research, 2023
Introduction Interstitial lung disease (ILD) may be difficult to distinguish from other respiratory diseases due to overlapping clinical presentation. Recognition of ILD is often late, causing delay which has been associated with worse clinical outcome ...
Iris G. van der Sar, Marlies S. Wijsenbeek, Gert-Jan Braunstahl, Jason O. Loekabino, Anne-Marie C. Dingemans, Johannes C. C. M. In ‘t Veen, Catharina C. Moor   +6 more
doaj   +1 more source

A multidisciplinary approach to the diagnosis of antisynthetase syndrome

Frontiers in Medicine, 2022
Antisynthetase syndrome is a subtype of idiopathic inflammatory myopathy, strongly associated with the presence of interstitial lung disease. Diagnosis is made by identifying myositis-specific antibodies directed against aminoacyl tRNA synthetase, and ...
Matthew Wells, Sughra Alawi, Kyaing Yi Mon Thin, Harsha Gunawardena, Harsha Gunawardena, Adrian R. Brown, Anthony Edey, John D. Pauling, John D. Pauling, Shaney L. Barratt, Huzaifa I. Adamali   +10 more
doaj   +1 more source

Predictors and changes of physical activity in idiopathic pulmonary fibrosis

BMC Pulmonary Medicine, 2022
Background Different clinical predictors of physical activity (PA) have been described in idiopathic pulmonary fibrosis (IPF), but studies are lacking evaluating the potential role of muscle strength and anxiety and depression symptoms in PA limitation ...
Diana Badenes-Bonet, Anna Rodó-Pin, Diego Castillo-Villegas, Vanesa Vicens-Zygmunt, Guadalupe Bermudo, Fernanda Hernández-González, Karina Portillo, Juana Martínez-Llorens, Roberto Chalela, Oswaldo Caguana, Jacobo Sellarés, Maria Molina-Molina, Xavier Duran, Joaquim Gea, Diego Agustín Rodríguez-Chiaradia, Eva Balcells   +15 more
doaj   +1 more source

Clinicoserological features of antisynthetase syndrome (ASyS)-associated interstitial lung disease presenting to respiratory services: comparison with idiopathic pulmonary fibrosis and ASyS diagnosed in rheumatology services

BMJ Open Respiratory Research, 2021
Introduction Antisynthetase syndrome (ASyS) is a rare autoimmune connective tissue disease (CTD), associated with autoantibodies targeting tRNA synthetase enzymes, that can present to respiratory (interstitial lung disease (ILD)) or rheumatology ...
Harsha Gunawardena, Huzaifa I Adamali, Havra H Adamali, Caroline Cotton, Ben Mulhearn, Hina Iftikhar, John David Pauling, Lisa Spencer   +7 more
doaj   +1 more source

Idiopathic pulmonary fibrosis cluster analysis highlights diagnostic delay and cardiovascular comorbidity association with outcome

ERJ Open Research, 2021
Introduction Idiopathic pulmonary fibrosis (IPF) prognosis is heterogeneous despite antifibrotic treatment. Cluster analysis has proven to be a useful tool in identifying interstitial lung disease phenotypes, which has yet to be performed in IPF. The aim
Jaume Bordas-Martínez, Ricard Gavaldà, Jessica G. Shull, Vanesa Vicens-Zygmunt, Lurdes Planas-Cerezales, Guadalupe Bermudo-Peloche, Salud Santos, Neus Salord, Carmen Monasterio, Maria Molina-Molina, Guillermo Suarez-Cuartin   +10 more
doaj   +1 more source

Personalised medicine in interstitial lung diseases

European Respiratory Review, 2018
Interstitial lung diseases in general, and idiopathic pulmonary fibrosis in particular, are complex disorders with multiple pathogenetic pathways, various disease behaviour profiles and different responses to treatment, all facets that make personalised ...
Maria A. Kokosi, George A. Margaritopoulos, Athol U. Wells   +2 more
doaj   +1 more source

Genetic and environmental factors in interstitial lung diseases: current and future perspectives on early diagnosis of high-risk cohorts

Frontiers in Medicine, 2023
Within the wide scope of interstitial lung diseases (ILDs), familial pulmonary fibrosis (FPF) is being increasingly recognized as a specific entity, with earlier onset, faster progression, and suboptimal responses to immunosuppression.
Stefan Cristian Stanel, Stefan Cristian Stanel, Jack Callum, Pilar Rivera-Ortega   +3 more
doaj   +1 more source